Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that
initially became smaller after taking erlotinib and then started to get bigger despite
continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug
administration for treatment of head and neck and colon cancer. The goal of the phase I
portion of this trial is to find out the highest dose of cetuximab that can be taken together
with erlotinib. This study will also give an idea of how well cetuximab shrinks lung cancer
when given with erlotinib.
The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that
initially became smaller after taking erlotinib or gefitinib and then started to get bigger
despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug
administration for treatment of head and neck and colon cancer. The goal of this phase is to
determine if cetuximab given with erlotinib causes lung cancers to shrink in size.